The above results indicate that the order of administration of IL-2 and IFN-α may affect the survival of patients with renal cell carcinoma, and more rigorous and in-depth research is needed to explain the mechanisms of cytokine combination therapy for renal cell carcinoma. The gene discussed is IFNA2; the disease is hereditary clear cell renal cell carcinoma.